Editor’s Briefing: September 11, 2026

In Short. Biohaven’s epilepsy Kv7 pill took an FDA partial hold days after a $350 million license; Novartis shed roughly 13 percent after three late-stage stumbles and drew a call for board change; Angelo de Claro sketched an Oncology Center of Excellence agenda of AI review and more U.S. trial seats; AbbVie’s Qulipta cleared a menstrual-migraine bar no drug owns; and CDMOs kept filling capacity while a Science study showed platinum chemo aging children’s livers.

---

Partial hold after the deal

The FDA placed a partial clinical hold on Biohaven’s BHV-7000 (opakalim), a selective Kv7.2/7.3 potassium-channel activator in focal epilepsy, after rodent tests flagged a metabolite whose human risk is still unclear. New enrollment stops; patients already randomized may continue dosing. The hold landed days after SK Biopharmaceuticals licensed the asset for $350 million upfront, another $50 million next year, milestones, and a package BioPharma Dive put at up to $795 million overall. RISE-3 is fully enrolled and still expected to read out in the second half of this year; RISE-2’s unfinished enrollment is paused while Biohaven runs more nonclinical work, a delay RBC told investors may matter for any approval path that needs both studies. Shares fell more than 10 percent. (Fierce Biotech; BioPharma Dive; BioSpace; FirstWord Pharma)

The mechanism claim under review is not efficacy — it is whether a rodent metabolite maps to human safety for a channel opener already sold once this summer.

Board pressure in Basel

Novartis shares fell about 13 percent this week after three separate late-stage hits: antibody-oligonucleotide conjugate del-desiran missed Phase 3 hand-opening time in myotonic dystrophy type 1 (the centerpiece of last year’s $12 billion Avidity buy); antisense pelacarsen lowered Lp(a) but did not cut cardiovascular risk; and CAR-T rapcabtagene autoleucel paused Phase 2 work after three patient deaths. A remibrutinib multiple-sclerosis win did not offset the tape. Artisan Partners’ David Samra, a top-20 holder, told Reuters chairman Giovanni Caforio should tighten deal oversight at board level — while still praising CEO Vas Narasimhan’s operating record. Fierce put the market-cap wipe near $30 billion. (BioSpace; BioSpace; Fierce Pharma)

The teachable object is capital allocation under RNA and neuromuscular ambition: bolt-on doctrine met a $12 billion exception, and three readouts in one week turned that exception into a board-governance story.

OCE after Pazdur

In his first interview as permanent director of the FDA’s Oncology Center of Excellence, Angelo de Claro vowed to keep Richard Pazdur’s groundwork while prioritizing staff retention and hiring, AI tools in review, streamlined oncology development and trials, more U.S. patient enrollment, and continued external engagement. He became the first senior drug-evaluation leader confirmed permanent in the current leadership churn (acting late 2025; permanent in May). OCE’s 2025 report tallied 17 new oncology molecules and 38 new indications. De Claro pointed to Revolution Medicines’ Rasonque (daraxonrasib), cleared more than six months ahead of its PDUFA date via real-time oncology review and a Commissioner’s National Priority Voucher, and said priority-voucher work will not slip other deadlines. (Fierce Pharma)

A label gap AbbVie wants

AbbVie’s oral CGRP antagonist Qulipta (atogepant) hit the primary endpoint in Phase 3 Luna for menstrual migraine: averaged across three cycles, migraine days in the perimenstrual window fell 1.2 days on drug versus 0.4 on placebo (0.80 fewer days versus control). Dosing was seven consecutive days starting three days before menses; all eight ranked secondary endpoints also cleared, with a safety profile called consistent with the known label. No therapy is specifically approved for menstrual migraine. AbbVie plans global regulatory submissions; Qulipta already holds chronic and episodic migraine labels and delivered about $1.04 billion in sales last year. (Fierce Pharma; FirstWord Pharma)

Plump’s handoff at Takeda

Andy Plump, Takeda’s R&D president since a 2015 Sanofi arrival, will retire in June 2027, stay until a successor is named, then help the transition and remain on the board through the June 2027 shareholder meeting. The exit follows August approvals for narcolepsy drug Orzeyful and blood-cancer Mimrylo, plus Phase 3 psoriasis data for TYK2 inhibitor zasocitinib — and sits beside earlier cell-therapy retreats. CEO Julie Kim called his tenure a “lasting foundation.” (Fierce Biotech; BioPharma Dive)

CDMOs keep filling

Samsung Biologics signed a $262 million manufacturing contract with an unnamed European pharma through 2033, production at Songdo, lifting cumulative contract value above $21.9 billion. Songdo still holds most of Samsung’s 845 kL global capacity (785 kL at home); Bio Campus II is slated to grow from 180 kL to 720 kL by 2032. Separately, Lonza plans a commercial PSD-4 spray-drying plant in Bend, Oregon, around 2029 (more than 80 jobs), and CordenPharma committed €80 million (~$96 million) to Caponago injectables capacity aimed at up to 500 million units a year. (Fierce Pharma; BioProcess International; Fierce Pharma)

NICE blanks twice-yearly PrEP

England’s NICE, in draft guidance, recommended against NHS coverage of Gilead’s twice-yearly lenacapavir for HIV prevention, citing uncertainties in clinical evidence and the economic model. MHRA cleared the PrEP use as Yeytuo; the U.S. brand is Yeztugo. NICE noted oral generic PrEP and GSK’s two-monthly cabotegravir (Apretude) as existing options, and said lenacapavir has not been head-to-head against cabotegravir. The draft is not final. (Fierce Pharma)

Platinum ages the liver

A Science study of children treated with cisplatin and carboplatin for hepatoblastoma — drugs that lifted localized five-year survival from about 20 percent to more than 80 percent — found platinum exposure left liver samples with hundreds of mutations (about 2,200 on average), a burden more typical of adult livers, rising with dual-agent exposure. Blood cells carried fewer mutations than liver. Authors and a companion perspective urged lifelong survivorship monitoring past the third decade; the claim is mutation burden and monitoring need, not a guaranteed second cancer. (STAT News)

What to watch

pdufa.bio and today’s regulatory packet put Telix’s TLX101-Px (Pixclara) glioma PET decision on today’s calendar (September 11), Ultragenyx UX111 (ABO-102) for Sanfilippo A on September 19, Merck Winrevair (HYPERION) label work on September 21, Mirum/Incyte zilurgisertib on September 26, and a September 30 cluster with Novo Mim8 (denecimig) and Scholar Rock apitegromab. Roche Tecentriq adjuvant MSI-H colon follows October 9.

Open mechanism questions from this tape: whether Biohaven’s rodent metabolite is species-specific or a real human Kv7 liability before RISE-2 can finish; whether Novartis’s Avidity RNA platform still earns a $12 billion thesis after del-desiran’s miss; whether OCE AI-and-voucher speed can scale without starving standard reviews; and whether a seven-day perimenstrual Qulipta regimen becomes the first labeled answer for menstrual migraine.